LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Endo International plc (“Endo International” or the “Company”) (Nasdaq: ENDP) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On June 8, 2017, the United States Food and Drug Administration requested that Endo International pull its powerful opioid painkiller Opana ER off the market due to its “high risk of abuse and potential to help spread HIV and hepatitis C.”
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.